182 related articles for article (PubMed ID: 38686050)
1. A comparative
Karim S; Alghanmi AN; Jamal M; Alkreathy H; Jamal A; Alkhatabi HA; Bazuhair M; Ahmad A
Oncol Res; 2024; 32(5):817-830. PubMed ID: 38686050
[TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
[TBL] [Abstract][Full Text] [Related]
5. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
[TBL] [Abstract][Full Text] [Related]
6. SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Komatsu S; Nomiyama T; Numata T; Kawanami T; Hamaguchi Y; Iwaya C; Horikawa T; Fujimura-Tanaka Y; Hamanoue N; Motonaga R; Tanabe M; Inoue R; Yanase T; Kawanami D
Endocr J; 2020 Jan; 67(1):99-106. PubMed ID: 31776304
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin inhibits p-gp function and early autophagy and improves the sensitivity to the antitumor effect of doxorubicin.
Zhong J; Sun P; Xu N; Liao M; Xu C; Ding Y; Cai J; Zhang Y; Xie W
Biochem Pharmacol; 2020 May; 175():113856. PubMed ID: 32061772
[TBL] [Abstract][Full Text] [Related]
8. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin.
Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K
Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008
[TBL] [Abstract][Full Text] [Related]
9. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor.
Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP
Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363
[TBL] [Abstract][Full Text] [Related]
10. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
Papadopoli D; Uchenunu O; Palia R; Chekkal N; Hulea L; Topisirovic I; Pollak M; St-Pierre J
Neoplasia; 2021 Apr; 23(4):391-399. PubMed ID: 33784591
[TBL] [Abstract][Full Text] [Related]
11. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines.
Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC
Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211
[TBL] [Abstract][Full Text] [Related]
12. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
Chu C; Lu YP; Yin L; Hocher B
Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
[TBL] [Abstract][Full Text] [Related]
13. A sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin comparison with insulin shows important effects on Zn
Olgar Y; Turan B
Can J Physiol Pharmacol; 2019 Jun; 97(6):528-535. PubMed ID: 30444646
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells.
Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP
Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
Bardaweel S; Issa A
J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
[TBL] [Abstract][Full Text] [Related]
16. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
17. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells.
Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
19. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
20. The role of SGLT2 inhibitors in managing type 2 diabetes.
Tat V; Forest CP
JAAPA; 2018 Jun; 31(6):35-40. PubMed ID: 29846314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
